Oxford Univ spin off gets $20 mn for retinal gene therapy

Posted in News, World

Oxford University and Wellcome Trust-subsidiary Syncona have formed a firm named Nightstar for developing retinal gene therapies

Syncona, an independent subsidiary of the Wellcome Trust, has made a $19.60 million (£12 million) investment in NightstaRx, which is a spin-out from the University of Oxford and its research commercialization company Isis Innovation. Nightstar will focus on the development and commercialization of therapies for retinal dystrophies, which are degenerative conditions affecting vision.

• Continue Reading

Alarm bells over antibiotic resistance

Posted in News, World

The World Health Organisation’s most comprehensive report to date sounds a warning that we are entering a world where antibiotics have little effect.

THE World Health Organisation (WHO) has sounded a warning that many types of disease-causing bacteria can no longer be treated with the usual antibiotics and the benefits of modern medicine are increasingly being eroded.

• Continue Reading